<DOC>
	<DOCNO>NCT02027701</DOCNO>
	<brief_summary>This study extension study pivotal study IgPro20_3003 ( NCT01545076 ) . The purpose extension study investigate long-term treatment CIDP IgPro20 , regard safety efficacy . Subjects complete subcutaneous ( SC ) Week 25 successfully rescue CIDP relapse SC Treatment Period pivotal study IgPro20_3003 ( NCT01545076 ) option receive open-label low-dose IgPro20 ( 0.2 g/kg bodyweight [ bw ] ) weekly 48 week . Subjects relapse low-dose IgPro20 either return high-dose IgPro20 ( 0.4 g/kg ) immediately discontinue , depend investigator 's judgment . Subjects return high-dose IgPro20 continue high-dose complete total 48 week IgPro20 treatment . If subject successfully recover CIDP relapse within 4 week , withdrawn . The treatment duration 48 week , follow completion visit ( week 49 ) .</brief_summary>
	<brief_title>Extension Study Maintenance Treatment With Subcutaneous Immunoglobulin ( IgPro20 ) Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP )</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects complete pivotal study IgPro20_3003 ( SC Week 25 ) successfully rescue CIDP relapse SC Treatment Period pivotal study IgPro20_3003 ( NCT01545076 ) . Written inform consent study participation obtain undergoing studyspecific procedure . Subject unable directly transition study IgPro20_3003 . New medical condition and/or social behavior ( ie , alcohol , drug , medication abuse ) participation study IgPro20_3003 judgment investigator could increase risk subject , interfere evaluation investigational medicinal product , and/or conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>